Prof.  

Richard Warren

, United Kingdom


Chair

Psoriasis treatment
Review and Updates
12 October 2019 13:15 - 14:45 More ...

Presentations

Choosing the right new therapeutics 12 October 2019 14:15 - 14:35 More ...
Tildrakizumab provides early predictability of response in patients with moderate-to-severe psoriasis: results from reSURFACE 1 and reSURFACE 2 phase 3 trials 09 October 2019 00:00 - 00:00 More ...
Comparison of Dermatology Quality of Life Index for Novel Treatments of Moderate to Severe Plaque Psoriasis: A Network Meta-Analysis 09 October 2019 00:00 - 00:00 More ...

Abstracts

Tildrakizumab provides early predictability of response in patients with moderate-to-severe psoriasis: results from reSURFACE 1 and reSURFACE 2 phase 3 trials Psoriasis More
Comparison of Dermatology Quality of Life Index for Novel Treatments of Moderate to Severe Plaque Psoriasis: A Network Meta-Analysis Psoriasis More